Garry A. Nicholson has been appointed senior vice president, general manager of Pfizer’s newly created Oncology Business Unit. Reporting to Ian Read, president of Pfizer Worldwide Pharmaceutical Operations, Mr. Nicholson will serve as head of the company's oncology franchise, with direct responsibility for clinical development, medical affairs, commercial development, sales and marketing.
   
“Garry is a highly regarded and accomplished executive whose experience in the global oncology market makes him exceptionally qualified to lead this important new growth area for Pfizer,” Mr. Read said. “The oncology market is expected to grow significantly in the next decade. This is being driven by breakthrough science, the rapid uptake of new agents that meet high unmet medical need and treatments that are enabling cancer patients to live longer.”
   
Mr. Nicholson is a senior pharmaceutical executive with extensive experience in product development, marketing, sales and general management on a worldwide basis. He joins the company from Eli Lilly and Co., where he spent more than 10 years as executive director of the U.S. Oncology Business Unit and subsequently in an expanded role as Global Oncology Platform Leader. In the latter role, Mr. Nicholson was responsible for the global oncology franchise, including the oncology therapeutic area strategy, portfolio management, Phase II/III development, global integration of oncology medical and marketing strategies, regulatory submissions and approvals, and licensing and partnerships. Mr. Nicholson was also directly accountable for the company’s oncology drug development budget and review of country and regional forecasts and income statements. In addition, he played a key leadership role in business development and licensing initiatives in oncology. Under Mr. Nicholson’s leadership, Lilly’s global oncology sales exceeded $2.5 billion in 2007.

Peter Soelkner will be heading a number of divisions at the Ravensburg-based business of Vetter Pharma-Fertigung GmbH & Co. KG, which specializes in the filling of prefilled injection systems. He will be responsible for global key account management, corporate marketing, supply chain management and project management. Mr. Soelkner will be joining the current managing directors Max Horn and Thomas Otto in handling company business.
   
Mr. Soelkner has 10 years of sales experience in the international pharmaceutical and biotech industries. He previously served as vice president Global KAM at Stedim Biotech, USA, where managed the successful merger of Sartorius and Stedim, now Sartorius Stedim Biotech. From 2003 to 2007 Mr. Soelkner served as director of the key account management at Vetter. He managed the implementation of the “End to End Supply Chain Organization” concept at Vetter, attaining an "Operational Excellence Class A" certification for the company within a record time of 11 months.
   
“Peter Soelkner is our candidate of choice," said Mr. Horn. “He has the necessary experience in international management and a great deal of expertise in the pharma and biotech industries, plus he is already completely familiar with the structures and products of our company. This makes him the perfect man for us.”

Steven M. Klosk has been appointed president and chief executive officer and a member of the board of directors of Cambrex. James A. Mack, president and chief executive officer since 1995 and chairman since 1999, has announced plans to retire. The company will separate the positions of chairman and chief executive officer and John R. Miller, currently lead director, will assume the position of non-executive chairman of the board. Mr. Mack will remain a board member and advisor until his retirement on June 30, 2008.
    
Mr. Klosk joined Cambrex in October 1992 as vice president, administration. He held several positions of increasing responsibility serving as executive vice president, administration, executive vice president and chief operating officer for Cambrex Pharma and BioPharmaceutical Business Unit, and assumed direct responsibility for the BioPharmaceutical Business Unit serving as chief operating officer. In January 2007 he was appointed executive vice president and chief operating officer for the Corporation.  
   
"I have enjoyed my many years with Cambrex and now is the right time to turn the Company over to new leadership. I am confident that with his many years with Cambrex, Steve will ably continue the pattern of growth that is so much a part of the Company," commented Mr. Mack.
   
"I am excited about the opportunity to lead the Cambrex team as we focus on our growth initiatives in proprietary products and polymeric drug delivery, highly potent compounds, controlled substances and our growing pipeline of new custom development products. In addition, we are well positioned to leverage our recently completed facility near Milan, Italy to support our leading position in generic active pharmaceutical ingredients," said Mr. Klosk. "I am extremely grateful to Jim for his many years of outstanding service to Cambrex and for his personal mentorship."